Related Experiment Videos
A crossover study of triptorelin and leuprorelin acetate
1Deprtment of Obstetrics and Gynaecology, Prince of Wales Hospital, The Chinese University of Hong Kong, China. thcheung@cuhk.edu.hk
Fertility and Sterility
|August 6, 2000
Summary
Triptorelin and leuprorelin acetate show comparable potency and side effects for pituitary-ovarian function. Triptorelin offers a longer duration of action, allowing for extended dosing intervals in endometriosis treatment.
Area of Science:
- Reproductive endocrinology
- Pharmacology
Background:
- Pelvic endometriosis is a common gynecological condition.
- Hormonal therapies like GnRH agonists are used to manage endometriosis.
- Triptorelin and leuprorelin acetate are commonly used GnRH agonists.
Purpose of the Study:
- To compare the efficacy, safety, and duration of action of triptorelin and leuprorelin acetate.
- Evaluate hormonal suppression and recovery after treatment for endometriosis.
Main Methods:
- Prospective, double-blind, crossover clinical study.
- Fifty-four patients with pelvic endometriosis received i.m. injections of triptorelin and leuprorelin acetate.
- Assessed menopausal symptoms, menstrual return, and hormonal levels (E2, FSH, LH).
Main Results:
- Both triptorelin and leuprorelin acetate demonstrated comparable potency in suppressing E2, FSH, and LH.
- Similar severity of menopausal symptoms and changes in lipid profiles and liver function were observed.
- Menstruation returned significantly earlier after leuprorelin acetate compared to triptorelin.
Conclusions:
- Triptorelin and leuprorelin acetate are equally potent in down-regulating pituitary-ovarian function with similar side effect profiles.
- Triptorelin exhibits a longer duration of action, enabling less frequent administration intervals.
- These findings support individualized treatment choices for endometriosis based on desired duration of suppression.